Legacy Financial Strategies’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.35M Sell
5,382
-412
-7% -$88.6K 0.21% 56
2026
Q1
$1.26M Sell
5,794
-103
-2% -$22.8K 0.23% 53
2025
Q4
$1.35M Sell
5,897
-462
-7% -$105K 0.24% 54
2025
Q3
$1.47M Sell
6,359
-12,664
-67% -$2.58M 0.27% 53
2025
Q2
$3.53M Sell
19,023
-90
-0.5% -$16.7K 0.69% 26
2025
Q1
$4M Buy
19,113
+482
+3% +$93.7K 0.87% 19
2024
Q4
$3.34M Buy
18,631
+80
+0.4% +$14.7K 0.72% 24
2024
Q3
$3.66M Buy
18,551
+67
+0.4% +$12.5K 0.81% 24
2024
Q2
$3.03M Buy
18,484
+1,756
+10% +$291K 0.73% 28
2024
Q1
$3.05M Buy
16,728
+620
+4% +$107K 0.79% 25
2023
Q4
$2.5M Buy
16,108
+44
+0.3% +$6.42K 0.71% 32
2023
Q3
$2.28M Buy
16,064
+597
+4% +$87.6K 0.73% 33
2023
Q2
$2.08M Buy
15,467
+1,497
+11% +$220K 0.7% 37
2023
Q1
$2.23M Buy
13,970
+868
+7% +$133K 0.83% 23
2022
Q4
$2.12M Buy
13,102
+882
+7% +$135K 0.88% 21
2022
Q3
$1.64M Sell
12,220
-1,631
-12% -$234K 0.76% 28
2022
Q2
$2.12M Buy
13,851
+506
+4% +$77.3K 1.05% 14
2022
Q1
$2.16M Sell
13,345
-110
-0.8% -$16K 0.92% 16
2021
Q4
$1.82M Buy
13,455
+420
+3% +$49.6K 0.79% 21
2021
Q3
$1.41M Buy
13,035
+888
+7% +$101K 0.66% 32
2021
Q2
$1.37M Buy
12,147
+716
+6% +$80.6K 0.66% 33
2021
Q1
$1.24M Buy
11,431
+542
+5% +$58K 0.65% 31
2020
Q4
$1.17M Buy
10,889
+246
+2% +$23.6K 0.6% 27
2020
Q3
$932K Buy
10,643
+217
+2% +$20.4K 0.54% 34
2020
Q2
$1.02M Buy
10,426
+286
+3% +$25.2K 0.79% 18
2020
Q1
$773K Buy
10,140
+960
+10% +$81.8K 0.73% 19
2019
Q4
$813K Buy
9,180
+898
+11% +$74.6K 0.66% 32
2019
Q3
$649K Buy
8,282
+947
+13% +$64.9K 0.58% 35
2019
Q2
$523K Buy
7,335
+535
+8% +$42.1K 0.49% 40
2019
Q1
$548K Buy
6,800
+588
+9% +$48.1K 0.47% 38
2018
Q4
$573K Buy
6,212
+289
+5% +$25.4K 0.57% 22
2018
Q3
$522K Buy
5,923
+125
+2% +$11.9K 0.53% 29
2018
Q2
$537K Buy
5,798
+158
+3% +$15.4K 0.48% 33
2018
Q1
$534K Sell
5,640
-53
-0.9% -$5.82K 0.52% 30
2017
Q4
$551K Buy
+5,693
New +$537K 0.59% 30

Other funds holding ABBV

Legacy Financial Strategies's ABBV Position: Q2 2026 in Review

Legacy Financial Strategies reduced its AbbVie (ABBV) stake by 7.1% in Q2 2026, selling an estimated $88.6K and leaving 5,382 shares worth $1.35M. The position accounts for 0.21% of the portfolio, ranked #56.

Legacy Financial Strategies first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $4M in Q1 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Legacy Financial Strategies held 5,382 shares of AbbVie worth $1.35M as of Q2 2026.
  • Legacy Financial Strategies sold 412 AbbVie shares in Q2 2026, an estimated $88.6K.
  • AbbVie made up 0.21% of Legacy Financial Strategies's portfolio in Q2 2026, its #56 holding.
  • Legacy Financial Strategies first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
  • Legacy Financial Strategies's AbbVie position peaked at $4M in Q1 2025.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Legacy Financial Strategies's 13F filing for Q2 2026, filed 21 Jul 2026.